Ad-hoc: Cantourage Group SE records strong growth in 2024 since the partial
legalisation of cannabis came into force

EQS-Ad-hoc: Cantourage Group SE / Key word(s): Quarter Results
Ad-hoc: Cantourage Group SE records strong growth in 2024 since the partial
legalisation of cannabis came into force

15-May-2024 / 07:44 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Not for release, publication or distribution, directly or indirectly, in or
into the United States of America, Australia, Canada or Japan or any other
jurisdiction in which such release, publication or distribution would be
unlawful. The important notes at the end of this announcement must be
observed.

Ad-hoc: Cantourage Group SE records strong growth in 2024 since the partial
legalisation of cannabis came into force

  * Revenue in April 2024 increased by around 160% compared to the same
    month last year

  * Significant increase in the number of cannabis patients recorded due to
    partial legalisation in April 2024

* Continued strong growth expected in financial year 2024

Berlin, 15 May 2024 - Cantourage Group SE (hereinafter "Cantourage," ISIN:
DE000A3DSV01, www.cantourage.com), a leading European cannabis production
and distribution company, recorded a significant increase in demand and
revenue growth of approximately 160% in April 2024 compared to the same
month last year. Revenue growth in the first quarter of 2024 remained below
expectations at approx. 26 % compared to the same period of the previous
year (revenue in Q1 2024: EUR 6.2 million, revenue in Q1 2023: EUR 4.8
million) due to the uncertain legal situation.

Due to the changes resulting from the "Cannabis Act," Cantourage assumes
that significant growth in revenue can be achieved in 2024 as a whole. The
company expects the "Cannabis Act" to provide significant impetus for
medical cannabis in 2024, as it is no longer a narcotic. This will lead to
simplifications in dispensing by pharmacies and prescriptions by doctors. It
is not yet possible to estimate how the trend will develop and how strongly
it will affect Cantourage's revenue and earnings performance. In principle,
however, Cantourage expects to benefit greatly from the new legal framework
in 2024 as a whole.

The figures relate to an unaudited pro forma consolidation of the operating
subsidiaries.

About Cantourage

Cantourage is a leading European producer and distributor of cannabis-based
medicinal preparations and drugs. The Berlin-based company was founded in
2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and
Patrick Hoffmann. With an experienced management team and its "Fast Track
Access" platform, Cantourage enables producers from around the world to
become part of the growing European medical cannabis market faster, easier
and more cost-effectively by processing and distributing their cannabis raw
materials and extracts. In this context, Cantourage ensures compliance with
the highest European pharmaceutical quality standards at all times. The
company offers pharmaceutical-grade products in all relevant market
segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was
listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed
under ticker symbol "HIGH."

Further information: www.cantourage.com

This announcement does not constitute a public offer or an advertisement for
a public offer to sell securities, in particular not within the meaning of
Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact at Cantourage:

Bernd Fischer

Phone +49 (0)30 4701 350 - 50

fischer@cantourage.com


End of Inside Information

---------------------------------------------------------------------------

15-May-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Cantourage Group SE
                   Feurigstraße 54
                   10827 Berlin
                   Germany
   E-mail:         info@cantourage.com
   Internet:       https://www.cantourage.com/
   ISIN:           DE000A3DSV01
   WKN:            A3DSV0
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt (Scale), Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1902791

End of Announcement EQS News Service
---------------------------------------------------------------------------

1902791 15-May-2024 CET/CEST